Sunday Times – Irish firm Open Orphan #ORPH lined up for role in coronavirus fight
by Brian Carey An Irish company is on call to play a part in the fight against the spread of the Wuhan coronavirus. Open Orphan, which is listed on the Alternative Investment Market in London, has just completed the purchase of hVivo, a British company which owns the largest commercial quarantine clinic in northern Europe. […]
Open Orphan #ORPH – Results of Placing and Subscription
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY […]
Open Orphan #ORPH – Proposed Placing to raise a minimum of £5 million to fund growth and convert hVIVO proposal pipeline
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE […]
Cathal Friel talks to Zak Mir about ‘sleeping giant’ hVIVO, and his plans for the new enlarged Open Orphan #ORPH
Open Orphan #ORPH announced the completion of its acquisition of UK-based hVivo Plc on Monday, 20th January 2020. Cathal Friel, Executive Chairman of Open Orphan commented, “I am hugely excited by the combination of Open Orphan and hVIVO. We have a fantastic team, substantial revenue potential and the opportunity to grow quickly in the year […]
Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext Growth of its existing ordinary share capital and the new ordinary shares to be issued as consideration in connection with the Merger, will commence at 8.00 a.m. […]
Cathal Friel, Open Orphan #ORPH CEO confirms to Proactive Investors that the hVIVO deal is done
Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. Cathal also provides some news on the Genomic Database and explains how he expects hVIVO to make a profit.
Open Orphan #ORPH – Second Closing of the hVIVO Offer, No extension of the Offer
Second Closing of the Offer No extension of the Offer Introduction On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the “Offer”). Under the terms of the Offer, hVIVO […]
Open Orphan #ORPH CEO Cathal Friel discusses contract wins & hVIVO #HVO merger on the Vox Markets podcast
Cathal Friel, CEO of Open Orphan #ORPH discusses their new 3-year contract with a tier one German pharmaceutical company and progress on their merger with Hvivo #HVO
BRR Media interviews Cathal Friel, CEO of Open Orphan #ORPH
BRR Media interviews Cathal Friel, CEO of Open Orphan #ORPH. Click on the logo to listen.
Irish Independent – Open Orphan signs ‘significant’ revenue generating contract
by Ellie Donnelly Open Orphan, a Europe-focused pharma services company specialising in rare disease and so-called orphan drugs, has signed a contract with a German-based research-driven pharmaceutical company. Open Orphan said the contract guarantees “significant” annual income, with work under the deal to commence this month. This contract will see Venn Life Sciences, part of […]